Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

CARLSBAD, Calif. –(BUSINESS WIRE)–Jun. 4, 2026– Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at